REG-Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
Genmab announced positive topline results from the Phase 3 EPCORE DLBCL-4 trial, showing epcoritamab plus lenalidomide significantly improved progression-free survival in relapsed/refractory diffuse large B-cell lymphoma. The combination reduced the risk of disease progression or death by 60% (HR 0.40) compared to standard-of-care chemoimmunotherapy, with a p value of less than 0.0001.
Key figures
- Drug Name
- epcoritamab (GEN3013, DuoBody-CD3xCD20)
- Phase Of Trial
- Phase 3
- Hr pfs
- 0.40
- Hr pfs ci
- [0.30, 0.55]
- Trial name
- EPCORE DLBCL-4
- P value pfs
- < 0.0001
- Risk reduction percent
- 60%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.